Search Results
Your search for ,aDd matches 943 pages
Showing 901 - 943Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Chemoradiation Plus Nonsurgical Management of Rectal Cancer Appears Safe, May Offer Better Quality of Life Than Surgery
A retrospective review of clinical data on 145 patients with stage I to III rectal cancer indicates that patients who achieved complete response after treatment with chemoradiation and systemic chemotherapy had similar 4-year survival rates regardless of whether they had immediate surgery or...
No Survival Difference for Adjuvant Capecitabine vs 5-FU With or Without Oxaliplatin in Stage III Colon Cancer
In an analysis reported in The Lancet Oncology, Schmoll et al found no difference in survival outcomes with adjuvant capecitabine vs fluorouracil (5-FU)/leucovorin with or without oxaliplatin in patients with stage III colon cancer and no adverse impact of adjuvant oxaliplatin on post-relapse...
SABCS 2014: BOLERO-3: Everolimus Plus Trastuzumab/Paclitaxel Misses the Mark in First-Line HER2 Advanced Breast Cancer
The addition of everolimus to weekly trastuzumab (Herceptin) plus paclitaxel did not improve outcomes in the phase III BOLERO-1/TRIO-019, but did provide a “signal” in the hormone receptor–negative subset. The study was reported at the 2014 San Antonio Breast Cancer Symposium by...
SABCS 2014: Ovarian Suppression Added to Hormonal Therapy Reduces Risk of Recurrence in Some Premenopausal Women
Results of the large international SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of recurrence in premenopausal women with hormone receptor–positive breast cancer at high enough risk to be treated with ...
ASH 2014: T-Cell Acute Lymphoblastic Leukemia Outcomes Excellent, Even for 'Poor-Risk' Group
Outcomes in children with T-cell acute lymphoblastic leukemia (ALL), which has traditionally been considered a poor-prognosis cancer, are better than expected, even for the early thymic precursor (ETP) phenotype, according to investigators from the Children’s Oncology Group (COG) who...
Postdiagnosis Aspirin Use Associated With Reduced Disease-Specific Mortality Only in High-Risk Subgroup of Men With Nonmetastatic Prostate Cancer
A recent analysis of a large clinical database indicated that postdiagnosis aspirin use was associated with a 57% reduction in prostate cancer–specific mortality among men with nonmetastatic prostate cancer. In a study in a prospective cohort reported in the Journal of Clinical Oncology,...
14 Million Major Medical Conditions Attributable to Cigarette Smoking
At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...
ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma
The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...
Little Molecular Difference and No Prognostic Effect of Clinical HER2 Status in Context of Intrinsic Breast Cancer Subtypes
In a study reported in the Journal of the National Cancer Institute, Prat et al found that there was little difference in downstream gene or protein expression according to intrinsic breast cancer subtypes among clinical HER2-positive vs -negative breast cancers and that clinical HER2 status did...
Oncologists Respond Rapidly to Clinical Trial Evidence on Use of EGFR Inhibitors
Use of panitumumab (Vectibix) and cetuximab (Erbitux) in patients with metastatic colorectal cancer decreased significantly after the publication of clinical trial evidence that anti-EGFR antibodies should be restricted to wild-type KRAS tumors, subsequent ASCO guidelines recommending testing for...
Improved Prognosis Seen in Older Women With Mammography-Detected Breast Cancer
Mammography-detected breast cancer is associated with a shift to earlier stage diagnosis in older women, subsequently reducing the rate of more advanced, difficult-to-treat cases, according to a new study by Malmgren et al published in the journal Radiology. The findings lend support to regular...
New Molecular Test Increases Odds of Correct Surgery for Thyroid Cancer Patients
The routine use of a molecular testing panel developed at the University of Pittsburgh Medical Center greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, reported researchers from the University of Pittsburgh Cancer Institute. The ...
Study Identifies Novel Genomic Changes in Lung Adenocarcinoma
Researchers from Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other centers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these mutations could potentially identify a...
American College of Physicians Issues Guideline Recommending Against Routine Pelvic Exams for Asymptomatic Women
A new evidence-based clinical practice guideline from the American College of Physicians (ACP) is recommending that physicians should not offer routine pelvic examinations to asymptomatic, average-risk, nonpregnant women. The recommendation stems from a review of 52 published articles from 1946...
Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy
The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract...
No Differences in Surgical Outcomes With Four Different Chemotherapy Regimens Plus Preoperative Radiotherapy in Rectal Cancer
As reported in the Journal of Clinical Oncology by O’Connell et al, the National Surgical Adjuvant Breast and Bowel Project (NSABP) Trial R-04 is assessing four chemotherapy regimens given concurrently with preoperative radiotherapy in order to help identify optimal treatment in patients with ...
Phase II Feasibility Study Tests Four Molecular-Based Hypotheses in Advanced Colorectal Cancer
In a phase II feasibility study (MRC FOCUS3) reported in British Journal of Cancer, Maughan et al used KRAS and BRAF mutation status and topoisomerase-1 expression status to randomly assign patients with advanced colorectal cancer to molecular hypothesis–driven treatment or control treatment. ...
ASCO Releases Clinical Practice Guideline on Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein, and these patients can benefit from HER2-targeted therapies. The American Society of Clinical Oncology recently released a clinical practice guideline on systemic therapy for patients with advanced...
High Circulating Tumor Cell Count at Baseline and Increases in Count During Treatment Linked to Reduced Survival in Metastatic Breast Cancer
In a pooled analysis of individual patient data reported in The Lancet Oncology, Bidard et al found that baseline circulating tumor cell counts and increases in counts during treatment were highly prognostic in patients with metastatic breast cancer beginning new treatment and that addition of...
Blood Test Could Improve Treatment for Children With Late-Stage Neuroblastoma
Research by Viprey et al has found that the detection of neuroblastoma mRNAs in peripheral blood and bone marrow aspirates from children diagnosed with stage IV neuroblastoma are independent predictors of event-free survival and overall survival. Their findings could help identify children with...
New Society Launched for Advanced Practitioners in Hematology and Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHO) announced its launch as a new organization focused on meeting the unique educational and professional needs of the advanced practitioner in hematology and oncology. The formation of the Society was made public January 26, 2014,...
New Clues May Link Hereditary Cancer Genes to Increased Risk of Cancer From Alcohol
In laboratory experiments conducted on human cell lines at the Johns Hopkins Sidney Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by acetaldehyde, a ...
Cetuximab Fails to Improve Survival in Nonoperable Esophageal Cancer
More data have emerged that discount the potential for benefit with epidermal growth factor receptor (EGFR) inhibitors in esophageal cancer. The latest comes from the RTOG 0436 randomized phase III trial in patients with nonoperable esophageal cancer, the results of which were presented at the 2014 ...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer
Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease
Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...
New Molecular Diagnostics Platform Enables Rapid Detection of BRAF V600 Mutations
A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented at the AACR-NCI-EORTC International...
Survival Advantage Seen in Glioblastoma Patients Taking Valganciclovir
Valganciclovir (Valcyte), a drug used to treat cytomegalovirus (CMV) eye infections in people with HIV/AIDS, may lengthen survival in patients with glioblastoma, a Swedish study has found. The researchers evaluated 50 patients with glioblastoma who received valganciclovir as an add-on to standard...
Breastfeeding for More Than 6 Months May Protect Against Breast Cancer in Nonsmoking Women
A new analysis has found that breastfeeding for more than 6 months may safeguard nonsmoking mothers against breast cancer. However, the same does not seem to hold true for mothers who smoke. Published early online in the Journal of Clinical Nursing, the findings add to the list of benefits of...
FDA Approves Dolutegravir to Treat HIV-1 Infection
The U.S. Food and Drug Administration (FDA) today approved dolutegravir (Tivicay), a new drug to treat HIV-1 infection. Dolutegravir is an oral integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. The drug is taken in combination with other...
Study Analyzes Oncologists’ Attitudes Regarding Patient-Reported Outcomes
A recent study published in the Journal of Oncology Practice assessed the feasibility and value of incorporating patient reported outcomes into oncology practice. Although previous research has shown that using patient-reported outcomes in oncology can improve physician-patient communication and...
FDA Warns of Rare but Serious Skin Reactions with Acetaminophen
The U.S. Food and Drug Administration (FDA) is informing the public that acetaminophen has been associated with a risk of rare but serious skin reactions. These skin reactions, known as Stevens-Johnson Syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis, can...
PET/CT Superior to Bone Marrow Biopsy for Diagnosis and Prognosis of Lymphoma Patients
A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma—a key factor in tailoring patient management plans—has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine. Imaging with...
Difference in Breast Cancer Survival Between Black and White Women Has Not Changed Substantially
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced...
ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma
Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...
ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma
A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...
Mammogram Tool Improves Some Breast Cancer Detection but Also Increases False Alarms
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found. A new study shows that computer-assisted detection (CAD) ...
Joint Statement on the President's Budget from ASCO, Community Oncology Alliance, ION Solutions, and the US Oncology Network
The President has released his proposed budget for fiscal year 2014, which proposes new reductions for cancer care services. Taken in combination with existing strains imposed by sequestration, this proposal threatens access to care for some of America's most vulnerable: elderly patients with ...
Cancer Drug Shortages Mean Higher Costs and Greater Risk for Patients
A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients, forcing treatment changes and delays that for some patients meant worse outcomes, more therapy-related complications, and higher costs. St. Jude Children’s Research Hospital...
NCCN Adds Two New Member Institutions
The National Comprehensive Cancer Network (NCCN) announced today the addition of two new NCCN Member Institutions: UC San Diego Moores Cancer Center in La Jolla, California, and the University of Colorado Cancer Center in Aurora, Colorado. "We are extremely pleased that UC San Diego Moores Cancer...
